|
Lucinda H. Cohen, B.S. in Chemistry (Indiana University); Ph.D. in Analytical Chemistry (University of Pittsburgh with Professor David Hercules); Alexander von Humboldt Postdoctoral Fellow (University of Muenster with Professor Dr. Franz Hillenkamp). Dr. Cohen is currently Director of the Preclinical Bioanalytical Group in the Drug Metabolism and Pharmacokinetics Department at Merck Research Laboratories in Rahway, NJ.
Dr. Cohen's research interests have focused on mass spectrometry, small molecule bioanalysis, and sample preparation approaches to increase the quality and speed of high throughput analysis in a drug discovery environment. In addition, her research has included novel approaches to minimize sample volume requirements from in vivo preclinical studies (microsampling, microfluidic analytics), tissue sample preparation, challenging chromatographic methodologies (chiral, normal phase, HILIC), on-line extraction methodologies, and mass spectrometric tissue imaging. Her work has resulted in over 25 peer-reviewed publications and book chapters.
Dr. Cohen has been a member of ASMS since 1990. She has presented, organized and chaired a session on the application of mass spectrometry at several ASMS Conferences. Currently, Dr. Cohen is co-chair of the ASMS Drug Metabolism Interest group. She has participated as an ad hoc reviewer for the NSF CAREER grant review committee. Dr. Cohen is also a member of the ACS. She has participated on the organizing committee of the North American Bioanalytical Forum, the Boston Society for Advanced Therapeutics Applied Pharmaceutical Analysis conference and was the 2008 Program Chair for the Chemical and Pharmaceutical Structure Analysis conference. She has served as an adjunct faculty member for Stevens Institute of Technology, Hoboken, NJ. She is a frequent reviewer for several scientific journals, including Analytical Chemistry, Analytical Biochemistry, Journal of Chromatography, and Journal of Pharmaceutical & Biomedical Analysis. |
Ashok R. Dongre, B.Sc. in Chemistry (Wilson College, Mumbai, India); M.Sc. in Physical Chemistry (University of Bombay); Ph.D. in Analytical Chemistry (Virginia Commonwealth University with Professor Vicki Wysocki) and Howard Hughes Postdoctoral Fellowship in Mol. Biotech. & Immunology (University of Washington with Dr. John Yates, III and Dr. Alexander Rudensky). Immediately following the postdoctoral fellowship, Dr. Dongre initiated his pharmacuetical research career, and he is currently Associate Director and Head of Protein Analytical Sciences at Bristol-Myers Squibb Co. in Princeton, NJ.
Dr. Dongre’s research interests focus on the application of qualitative as well as quantitative protein mass spectrometry for, i) target discovery, deconvolution and chemoproteomics to expand the druggable proteome space, ii) protein post-translational modification profiling and quantification to enable drug target MOA, validation and pharmacodynamics and iii) protein biomarker discovery, development and validation to support translational medicine. Another notable research effort includes his core contribution to the development of “Mobile Proton Model” (subject of 2009 Distinguished Contribution in Mass Spectrometry Award to Simon Gaskell & Vicki Wysocki) as a framework for understanding peptide fragmentation mechanisms. His research efforts and collaborations have resulted in over 29 peer-reviewed publications, book chapters and patent applications.
Dr. Dongre has been a member of ASMS since 1992 and has co-chaired workshops on the application of mass spectrometry in protein/peptide analyses at ASMS meetings. Dr. Dongre has participated as an ad hoc reviewer for 4 years on the NIH BECM and NIH NIAAA grant review committees. Dr. Dongre is also a member of the ACS, AACR and HUPO. He serves as a reviewer on several scientific journals, including JASMS, Analytical Chemistry, Analytical Biochemistry, Proteomics, Molecular and Cellular Proteomics, and J. Proteome Research.
|